-
1.
公开(公告)号:US09469615B2
公开(公告)日:2016-10-18
申请号:US13996361
申请日:2011-12-19
申请人: Christopher W. Boyce , Sylvia Joanna Degrado , Xiao Chen , Jun Qin , Robert D. Mazzola, Jr. , Younong Yu , Kevin D. McCormick , Anandan Palani , Dong Xiao , Robert George Aslanian , Jie Wu , Ashwin Umesh Rao , Phieng Siliphaivanh , Joey L. Methot , Hongjun Zhang , Elizabeth Helen Kelley , William Colby Brown , Qin Jiang , Jolicia Polivina Gauuan , Andrew J. Leyhane , Purakkattle Johny Biju , Pawan K. Dhondi , Li Dong , Salem Fevrier , Xianhai Huang , Henry M. Vaccaro
发明人: Christopher W. Boyce , Sylvia Joanna Degrado , Xiao Chen , Jun Qin , Robert D. Mazzola, Jr. , Younong Yu , Kevin D. McCormick , Anandan Palani , Dong Xiao , Robert George Aslanian , Jie Wu , Ashwin Umesh Rao , Phieng Siliphaivanh , Joey L. Methot , Hongjun Zhang , Elizabeth Helen Kelley , William Colby Brown , Qin Jiang , Jolicia Polivina Gauuan , Andrew J. Leyhane , Purakkattle Johny Biju , Pawan K. Dhondi , Li Dong , Salem Fevrier , Xianhai Huang , Henry M. Vaccaro
IPC分类号: C07D241/38 , C07D241/42 , A61K31/498 , A61K31/506 , A61K31/4985 , A61K31/55 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D451/02 , C07D471/08 , C07D487/04 , C07D487/08 , C07D403/06 , C07D471/04 , C07D471/10 , C07D491/107 , C07D498/04 , C07D403/12 , C07D401/06 , C07D403/14 , C07D409/14 , C07D413/06 , C07D241/44 , C07D417/14 , C07D491/048 , C07D498/10
CPC分类号: C07D241/42 , A61K31/498 , A61K31/4985 , A61K31/506 , A61K31/55 , A61K45/06 , C07D241/38 , C07D241/44 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D451/02 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , C07D498/04 , C07D498/10
摘要: The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.
-
公开(公告)号:US08927559B2
公开(公告)日:2015-01-06
申请号:US13878654
申请日:2011-10-06
申请人: Robert G. Aslanian , Christopher W. Boyce , Robert D. Mazzola, Jr. , Brian A. McKittrick , Kevin D. McCormick , Anandan Palani , Jun Qin , Haiqun Tang , Dong Xiao , Younong Yu , John P. Caldwell , Elizabeth Helen Kelley , Hongjun Zhang , Phieng Siliphaivanh , Rachel N. MacCoss , Joey L. Methot , Jolicia Polivina Gauuan , Qin Jiang , Andrew J. Leyhane , Purakkattle Johny Biju , Li Dong , Xianhai Huang , Ning Shao , Wei Zhou , Pawan K. Dhondi , Ashwin U. Rao
发明人: Robert G. Aslanian , Christopher W. Boyce , Robert D. Mazzola, Jr. , Brian A. McKittrick , Kevin D. McCormick , Anandan Palani , Jun Qin , Haiqun Tang , Dong Xiao , Younong Yu , John P. Caldwell , Elizabeth Helen Kelley , Hongjun Zhang , Phieng Siliphaivanh , Rachel N. MacCoss , Joey L. Methot , Jolicia Polivina Gauuan , Qin Jiang , Andrew J. Leyhane , Purakkattle Johny Biju , Li Dong , Xianhai Huang , Ning Shao , Wei Zhou , Pawan K. Dhondi , Ashwin U. Rao
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号: C07D239/91 , A61K31/517 , A61K31/5395 , A61K31/55 , A61K45/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/14 , C07D405/10 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/10 , C07D471/04 , C07D498/10
摘要: This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.
摘要翻译: 本申请提供式I化合物或其药学上可接受的盐,其中各个变量在本文中定义,以及制备这些化合物的方法,包含其的药物组合物及其用于治疗与CRTH2相关的疾病状态 受体。
-
公开(公告)号:US08881957B2
公开(公告)日:2014-11-11
申请号:US13129165
申请日:2009-11-16
申请人: Xianzhi Zhou , Dong Xiao You
发明人: Xianzhi Zhou , Dong Xiao You
CPC分类号: B65D51/165 , B65D2205/00 , F16K15/145 , F16K17/085 , F16K17/087 , Y10T137/7895 , Y10T137/7897
摘要: A relief valve (60) for a liquid container, the valve comprising a substantially conical body (50) extending into the container, and tapering inwardly away from an external wall of the container, at least one air inlet passage (62) through the substantially conical body; and a flexible diaphragm (53) extending over the conical body, being attached at its outer periphery around the substantially conical body and having a central opening surrounding the substantially conical body above the air inlet passage so as to seal the air inlet passage until the pressure within the container falls below a predetermined level.
摘要翻译: 一种用于液体容器的安全阀(60),所述阀包括延伸进入所述容器的基本上圆锥形的本体(50),并且从所述容器的外壁向内逐渐变细,至少一个空气入口通道(62) 圆锥体 以及在圆锥体上延伸的柔性隔膜(53),其周围围绕基本上圆锥形的主体附接在其外周边,并且具有围绕空气入口通道上方的基本上圆锥形的主体的中心开口,以便密封空气入口通道,直到压力 在容器内下降到预定水平以下。
-
公开(公告)号:US08754216B2
公开(公告)日:2014-06-17
申请号:US13245403
申请日:2011-09-26
申请人: Sapna S. Shah , Anandan Palani , Xianhai Huang , Dong Xiao , Sunil Paliwal , Hon-Chung Tsui , Michelle Laci Wrobleski , Ashwin U. Rao , Cheng Wang , Neng-Yang Shih
发明人: Sapna S. Shah , Anandan Palani , Xianhai Huang , Dong Xiao , Sunil Paliwal , Hon-Chung Tsui , Michelle Laci Wrobleski , Ashwin U. Rao , Cheng Wang , Neng-Yang Shih
IPC分类号: C07F7/02 , C07D215/12 , C07D215/16 , C07D213/02 , C07D405/00
CPC分类号: C07D401/04 , A61K31/4178 , A61K31/451 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/573 , A61K45/06 , C07D211/56 , C07D211/60 , C07D211/66 , C07D211/76 , C07D413/04 , C07D417/04 , C07D498/20
摘要: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
摘要翻译: 具有式I所示的一般结构的化合物或其药学上可接受的盐和/或溶剂合物可用于治疗由NK1受体介导的疾病或病症,例如各种生理疾病,症状或疾病,包括呕吐,抑郁,焦虑和咳嗽 。
-
公开(公告)号:US20130236588A1
公开(公告)日:2013-09-12
申请号:US13669270
申请日:2012-11-05
申请人: CHUN-WEI TSENG , HAN-WEI JIANG , JUN-PING LIU , HAO-DONG XIAO
发明人: CHUN-WEI TSENG , HAN-WEI JIANG , JUN-PING LIU , HAO-DONG XIAO
IPC分类号: B29C33/20
CPC分类号: B29C45/17
摘要: A mold assembly includes a first mold, a second mold, a first locking member, a second locking member and a pushing member. The first locking member is fixed in the first mold. The first locking member includes an engaging slot. The second locking member is pivotably mounted in the second mold. The second locking member includes an engaging portion. The engaging portion is engaged in the engaging slot to latch the first mold to the second mold, and the pushing member is adapted to push the second locking member to disengage the engaging portion from the engaging slot.
摘要翻译: 模具组件包括第一模具,第二模具,第一锁定构件,第二锁定构件和推动构件。 第一锁定构件固定在第一模具中。 第一锁定构件包括接合槽。 第二锁定构件可枢转地安装在第二模具中。 第二锁定构件包括接合部。 接合部分接合在接合槽中以将第一模具闩锁到第二模具,并且推动构件适于推动第二锁定构件以将接合部分从接合槽脱离。
-
6.
公开(公告)号:US20120316154A1
公开(公告)日:2012-12-13
申请号:US13515638
申请日:2010-12-09
申请人: Dong Xiao , Anandan Palani , Robert G Aslanian , Sylvia Degrado , Xianhai Huang , Wei Zhou , Michael Sofolarides , Xiao Chen
发明人: Dong Xiao , Anandan Palani , Robert G Aslanian , Sylvia Degrado , Xianhai Huang , Wei Zhou , Michael Sofolarides , Xiao Chen
IPC分类号: A61K31/55 , C07D495/04 , A61P11/06 , A61P1/00 , A61P17/06 , C07D491/048 , A61P29/00
CPC分类号: A61K31/55 , C07D491/048 , C07D495/04
摘要: The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.
摘要翻译: 本发明涉及式(I)的某些含内酰胺环的化合物及其药学上可接受的盐,其中D,E,X 1,R 1,R 2,R 3,R 4,R 9和R 10如本文所述。 此外,本发明涉及包含至少一种这样的化合物的药学上可接受的组合物,以及使用该化合物治疗或预防各种炎性疾病如类风湿性关节炎,炎性肠病,牛皮癣,哮喘和慢性阻塞性肺病的方法。
-
公开(公告)号:US20110245267A1
公开(公告)日:2011-10-06
申请号:US13139639
申请日:2009-12-18
申请人: Dong Xiao , Anandan Palani , Robert G. Aslanian
发明人: Dong Xiao , Anandan Palani , Robert G. Aslanian
IPC分类号: A61K31/497 , C07D513/04 , C07D417/14 , A61K31/437 , A61P11/00 , A61P1/00 , A61P25/00 , A61P3/10 , A61P3/08 , A61P3/04 , A61P3/00
CPC分类号: C07D513/04
摘要: The present invention relates to novel Piperidine and piperazine Derivatives, pharmaceutical compositions comprising the Piperidine and piperazine Derivatives and the use of these compounds of formula (I) for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
摘要翻译: 本发明涉及新颖的哌啶和哌嗪衍生物,包含哌啶和哌嗪衍生物的药物组合物以及这些式(I)化合物用于治疗或预防治疗过敏,过敏引起的气道反应,充血,心血管疾病, 糖尿病,糖尿病并发症,葡萄糖耐量降低或空腹血糖受损。
-
公开(公告)号:US20110098468A1
公开(公告)日:2011-04-28
申请号:US12967132
申请日:2010-12-14
申请人: Sunil Paliwal , Gregory A. Reichard , Cheng Wang , Dong Xiao , Hon-Chung Tsui , Neng-Yang Shih , Juan D. Arredondo , Michelle Laci Wrobleski , Anandan Palani
发明人: Sunil Paliwal , Gregory A. Reichard , Cheng Wang , Dong Xiao , Hon-Chung Tsui , Neng-Yang Shih , Juan D. Arredondo , Michelle Laci Wrobleski , Anandan Palani
IPC分类号: C07D207/14 , C07D207/12 , C07D263/20 , C07D401/04 , C07D211/40 , C07D413/12 , C07D487/10
CPC分类号: C07D498/10 , A61K31/166 , A61K31/40 , A61K31/4025 , A61K31/437 , A61K31/4375 , A61K31/438 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/537 , A61K31/5377 , A61K31/573 , A61K45/06 , C07D207/14 , C07D207/50 , C07D211/28 , C07D211/32 , C07D211/42 , C07D211/56 , C07D211/60 , C07D211/72 , C07D211/76 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D413/10 , C07D413/12 , C07D471/10 , C07D487/10 , C07D491/10 , C07D513/10
摘要: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
摘要翻译: 具有式(I)的NK1拮抗剂,其中Ar1和Ar2是任选取代的苯基或杂芳基,X1是醚,硫代或亚氨基键,R4和R5不都是H或烷基,其余的变量如 规范,用于治疗许多疾病,包括呕吐,抑郁,焦虑和咳嗽。 药物组合物。 还公开了治疗方法和与其它药剂的组合。
-
公开(公告)号:US07846453B2
公开(公告)日:2010-12-07
申请号:US11454635
申请日:2006-06-15
IPC分类号: A61K39/00 , A61K38/18 , C07K14/475
CPC分类号: C07K14/4756 , A61K38/00 , A61K2039/51 , C07K2319/00 , Y02A50/466
摘要: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
摘要翻译: 本发明涉及新型神经调节蛋白相关配体(NRG3),其包括其片段和变体,作为化合物神经调节蛋白家族的新成员。 本发明还涉及生产NRG3的方法和手段。 本发明的天然多肽的特征在于含有包括EGF样结构域,跨膜结构域和细胞质结构域的细胞外结构域。 编码这种多肽的分离的核苷酸序列,含有核苷酸序列的表达载体,用载体转化的重组宿主细胞,以及用于新型NRG3重组生产的方法也在本发明的范围内。
-
公开(公告)号:US20100190759A1
公开(公告)日:2010-07-29
申请号:US12750420
申请日:2010-03-30
申请人: Anandan PALANI , Xianhai HUANG , Dong XIAO , Sunil PALIWAL , Hon-Chung TSUI , Michelle Laci WROBLESKI , Ashwin U. RAO , Cheng WANG , Sapna S. SHAH , Neng-Yang SHIH
发明人: Anandan PALANI , Xianhai HUANG , Dong XIAO , Sunil PALIWAL , Hon-Chung TSUI , Michelle Laci WROBLESKI , Ashwin U. RAO , Cheng WANG , Sapna S. SHAH , Neng-Yang SHIH
IPC分类号: A61K31/573 , A61K31/4545 , A61K31/454 , A61K31/4523 , A61K31/451 , A61K31/4418 , A61P1/08 , A61P11/00 , A61P25/18 , A61P25/22 , A61P25/24 , A61P3/04 , A61P13/10 , A61P15/00 , A61P11/14
CPC分类号: C07D401/04 , A61K31/4178 , A61K31/451 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/573 , A61K45/06 , C07D211/56 , C07D211/60 , C07D211/66 , C07D211/76 , C07D413/04 , C07D417/04 , C07D498/20
摘要: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
摘要翻译: 具有式I所示的一般结构的化合物或其药学上可接受的盐和/或溶剂合物可用于治疗由NK1受体介导的疾病或病症,例如各种生理疾病,症状或疾病,包括呕吐,抑郁,焦虑和咳嗽 。
-
-
-
-
-
-
-
-
-